Amarin Corp Plc (AMRN)

[dogn]

See translated Mochida PR I posted at
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=168325803
as it more clearly describes collaboration than Amarin's PR:

Mochida Pharmaceutical Co., Ltd. licenses development and commercialization of new high-purity EPA formulation to Amarin Co., Ltd. Japanese rights are retained by Mochida
Release date 2018/06/13 03:50

Mochida Pharmaceutical Co., Ltd. announced on June 12 that it has signed a license agreement to license the right to develop and commercialize a new high-purity EPA formulation to Amarin, Ireland. Amarin has acquired the rights to "the United States and other regions," but at least Japan is not included in this, and Mochida retains Japan's rights. Mochida will receive a lump-sum contract payment, a milestone fee according to development progress, and a royalties according to the sales amount after the product is launched. Details such as the specific amount are not disclosed.

According to Mochida's public relations department, the new high-purity EPA formulation is not Epadel sold by the company, but a new one. Amarin will work on product development and commercialization in the United States and other countries using the new high-purity EPA formulation technology possessed by Mochida. Whether or not Mochida is developing a new high-purity EPA preparation in Japan is "not disclosed at all" (Public Relations Department).

Epadel is supplied with the drug substance from Nippon Suisan Kaisha, which has EPA's high-purity refining technology and mass production capacity. The contract with Amarin includes the supply of the drug substance from Nippon Suisan Kaisha.

Amarin is a pharmaceutical company that focuses on the commercialization and development of therapeutic agents for cardiovascular diseases, focusing on the potential of polyunsaturated fatty acids as pharmaceuticals, based on its abundant experience in lipid science. Vascepa, the company's first FDA-approved drug, is a high-purity EPA formulation available as a prescription drug in the United States and is used to improve blood triglyceride levels in patients with severe hypertriglyceridemia.